Rallybio Corp
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| FOR THE YEAR ENDEDDECEMBER 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2024 | 2023 |
| Revenue: | ||
| Collaboration and license revenue | $636 | $— |
| Total revenue | 636 | — |
| Operating expenses: | ||
| Research and development | 41,507 | 53,544 |
| General and administrative | 19,625 | 25,388 |
| Total operating expenses | 61,132 | 78,932 |
| Loss from operations | (60,496) | (78,932) |
| Other income: | ||
| Interest income | 4,216 | 6,147 |
| Other income | 744 | 262 |
| Total other income, net | 4,960 | 6,409 |
| Loss before equity in losses of joint venture | (55,536) | (72,523) |
| Loss on investment in joint venture | 2,239 | 2,041 |
| Net loss | $(57,775) | $(74,564) |
| Net loss per common share, basic and diluted | $(1.33) | $(1.84) |
| Weighted-average common shares outstanding, basic and diluted | 43,544,824 | 40,447,388 |
| Other comprehensive gain: | ||
| Net unrealized gain on marketable securities | 53 | 229 |
| Other comprehensive gain | 53 | 229 |
| Comprehensive loss | $(57,722) | $(74,335) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.